HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hepatic steatosis in type 1 diabetes.

Abstract
Islet autoimmunity in type 1 diabetes results in the loss of the pancreatic β-cells. The consequences of insulin deficiency in the portal vein for liver fat are poorly understood. Under normal conditions, the portal vein provides 75% of the liver blood supply. Recent studies suggest that non-alcoholic fatty liver disease (NAFLD) may be more common in type 1 diabetes than previously thought, and may serve as an independent risk marker for some chronic diabetic complications. The pathogenesis of NAFLD remains obscure, but it has been hypothesized that hepatic fat accumulation in type 1 diabetes may be due to lipoprotein abnormalities, hyperglycemia-induced activation of the transcription factors carbohydrate response element-binding protein (ChREBP) and sterol regulatory element-binding protein 1c (SREBP-1c), upregulation of glucose transporter 2 (GLUT2) with subsequent intrahepatic fat synthesis, or a combination of these mechanisms. Novel approaches to non-invasive determinations of liver fat may clarify the consequences for liver metabolism when the pancreas has ceased producing insulin. This article aims to review the factors potentially contributing to hepatic steatosis in type 1 diabetes, and to assess the feasibility of using liver fat as a prognostic and/or diagnostic marker for the disease. It provides a background and a case for possible future studies in the field.
AuthorsSimon E Regnell, Åke Lernmark
JournalThe review of diabetic studies : RDS (Rev Diabet Stud) Vol. 8 Issue 4 Pg. 454-67 ( 2011) ISSN: 1614-0575 [Electronic] Singapore
PMID22580727 (Publication Type: Journal Article, Review)
Chemical References
  • Insulin
  • Liver Glycogen
Topics
  • Adult
  • Animals
  • Carbohydrate Metabolism
  • Child
  • Diabetes Mellitus, Type 1 (complications, metabolism, physiopathology)
  • Endocrine System Diseases (complications, metabolism, physiopathology)
  • Fatty Liver (complications, metabolism)
  • Humans
  • Insulin (metabolism)
  • Lipid Metabolism
  • Liver (blood supply, metabolism, physiopathology)
  • Liver Glycogen (metabolism)
  • Non-alcoholic Fatty Liver Disease

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: